CytomX Therapeutics, Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. The filing also provides unaudited quarterly results, including the quarter ended December 31, 2019. CytomX is a clinical-stage oncology biotechnology company developing Probody antibody therapeutics; it has no approved products and has not generated product-sales revenue.
Financial performance and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $57.5 million | $59.5 million |
| Research and development expense | $131.6 million | $103.9 million |
| General and administrative expense | $36.8 million | $33.5 million |
| Operating loss | $110.9 million | $77.9 million |
| Net loss | $102.2 million | $84.6 million |
| Net loss per share, basic and diluted | $2.26 | $2.03 |
| Cash, cash equivalents and short-term investments, year-end | $296.1 million | $436.1 million |
| Working capital, year-end | $217.7 million | $347.6 million |
- Revenue was primarily collaboration, license, milestone and research-service revenue—not product sales. Bristol Myers Squibb contributed $47.7 million, or about 83% of 2019 revenue; AbbVie contributed $5.9 million and Amgen $3.9 million.
- Operating cash used was $140.5 million, compared with $75.5 million in 2018. Financing provided $1.6 million; investing provided $79.7 million, mainly reflecting maturities of short-term investments.
- At year-end, total liabilities were $290.2 million, including $230.2 million of deferred collaboration revenue and $27.7 million of operating lease liabilities. The balance sheet does not show financial borrowings. The company reported $51.1 million of stockholders’ equity.
- Management said existing capital resources were expected to fund planned operations for at least 12 months from issuance of the financial statements. The filing also cautions that spending and funding needs could vary and that additional funds will be needed.
- For Q4 2019, unaudited revenue was $8.3 million and net loss was $35.5 million, or $0.78 per share.
Material changes and notable items
- Net loss widened by $17.6 million year over year as operating expenses rose faster than revenue. R&D expense increased $27.8 million, principally from higher personnel and clinical/program costs, technology know-how acquisition, and license fees.
- Revenue declined $2.0 million. Lower AbbVie revenue, including the effect of a 2018 milestone, was substantially offset by higher BMS revenue. BMS revenue included $17.4 million of accelerated recognition after BMS terminated certain target programs.
- Cash, cash equivalents and short-term investments fell $140.0 million during 2019. The company reported no public equity offering proceeds in 2019; the prior-year balance included net proceeds of $134.6 million from a 2018 follow-on offering.
- Revenue recognition depends on management estimates of research-service progress and periods. The filing notes changes to estimated service periods for the AbbVie and Amgen collaborations.
Programs, outlook and principal risks
- CX-072 (PD-L1): CytomX shifted emphasis toward combination treatment after monotherapy data showed activity and a reported favorable severe immune-related adverse-event profile relative to historical comparisons. A Phase 2 study with ipilimumab began in October 2019; initial Stage 1 data were anticipated in 2020. A planned CX-072/vemurafenib combination was discontinued.
- CX-2009 (CD166 PDC): A Phase 2 expansion in hormone-receptor-positive, HER2-negative breast cancer was initiated in December 2019. Earlier dose-escalation data showed tumor shrinkage and unconfirmed responses; ocular toxicity associated with its DM4 payload was a notable adverse event.
- Partnered pipeline: AbbVie’s CX-2029 (CD71 PDC) remained in Phase 1/2. BMS advanced BMS-986249 into a randomized Phase 2 cohort expansion in February 2020, triggering a $10 million milestone to CytomX. BMS also began a Phase 1/2a study of BMS-986288 in September 2019. CytomX expected to advance an Amgen-partnered EGFR-CD3 candidate during 2020.
- Manufacturing risk: A contract manufacturer had a CX-072 production failure in November 2019. CytomX had arranged alternative suppliers, but warned that failure to deliver satisfactory product in Q2 2020 could temporarily suspend its ongoing trial. The company relies on third-party manufacturers and faces scale-up, stability and comparability risks.
- Funding and dilution: On February 27, 2020, CytomX entered an at-the-market sales agreement allowing up to $75 million of common-stock sales. This is potential financing, not proceeds reported as received. Equity issuance could dilute shareholders.
- Other risks and contingencies: Development remains early-stage and uncertain; trials may fail, be delayed, or reveal safety issues, and collaboration partners may change or end programs. The company reported an accumulated deficit of $417.2 million and expects significant ongoing losses. It disclosed no material litigation and no material off-balance-sheet arrangements.
Key facts investors should verify
- Whether the stated cash runway remains adequate after the reported $140.5 million of 2019 operating cash use and planned clinical-trial spending.
- Progress and updated efficacy and safety results from the CX-072/ipilimumab and CX-2009 Phase 2 studies, including whether early response and tolerability findings persist with more patients.
- Resolution of CX-072 supply issues, timing and adequacy of replacement manufacturing, and any resulting trial delays or formulation-bridging requirements.
- Actual timing and amount of any sales under the $75 million ATM facility, and resulting dilution.
- Reliance on BMS collaboration revenue and milestones, the remaining deferred revenue balance, and the potential effect of partner decisions or program terminations.